Changes in medicare reimbursement: Impact on therapy for benign prostatic hyperplasia

Current Urology Reports

Volumn 3, Issue 4, 2002, Pages 280-284

  Donnell, Robert F ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Benign Prostate Hyperplasia; Finasteride; Lower Urinary Tract Symptom; Terazosin; Transurethral Resection

Indexed keywords

ECONOMICS; HEALTH CARE COST; HUMAN; MALE; MEDICARE; PROSTATE HYPERTROPHY; REIMBURSEMENT; REVIEW; TRANSURETHRAL RESECTION; UNITED STATES;

HEALTH CARE COSTS; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MALE; MEDICARE; PROSTATIC HYPERPLASIA; TRANSURETHRAL RESECTION OF PROSTATE; UNITED STATES;

EID: 0036676953     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-002-0049-9     Document Type: Article

References (31)

1. Weis KA, Epstein RS, Huse DM, et al.: The costs of prostatectomy for benign prostatic hyperplasia. Prostate 1993, 22:325–234. DOI: 10.1002/pros.2990220407
2. Young DW, Saltman RB: Medical practice, case mix, and cost containment. A new role for the attending physician. JAMA 1982, 247:801–805. DOI: 10.1001/jama.247.6.801
3. Munoz E, Regan DM, Margolis IB, Wise L: Surgonomics: the identifier concept. Hospital charges in general surgery and surgical specialties under prospective payment systems. Ann Surg 1985, 202:119–125. DOI: 10.1097/00000658-198507000-00019
4. Munoz E, Soldano R, Laughlin A, et al.: Source of admission and cost: public hospitals face financial risk. Am J Public Health 1986, 76:696–697.
5. Munoz E, Wilkins S, Mallet E, et al.: Financial risk and hospital cost for elderly patients in non-age stratified urology DRGs. Urology 1989, 33:445–448. DOI: 10.1016/0090-4295(89)90048-4
6. Munoz E, Barrios E, Johnson H, et al.: Race and diagnostic related group prospective hospital payment for medical patients. J Natl Med Assoc 1989, 81:844–848.
7. Cohen E, Bernier D, Tam S, et al.: Data quality and DRGs: an assessment of the reliability of federal beneficiary discharge data in selected Manhattan hospitals. J Community Health 1985, 10:238–246. DOI: 10.1007/BF01371017
8. Mueller EJ, Zeidman EJ, Desmond PM, et al.: Reduction of length of stay and cost of transurethral resection of the prostate by early catheter removal. Br J Urol 1996, 78:893–896.
9. Holden MO: Meeting diagnostic related group goals for elderly patients. Health Soc Work 1989, 14:13–21.
10. Caputi MA, Heiss WA: The DRG revolution. Health Soc Work 1984, 9:5–12. DOI: 10.1300/J010v09n02_03
11. Bloom BS: Why such a hurry? Physician Exec 1990, 16:11–12.
12. Litwin MS, Sacher SJ, Cohen WS: The resource-based relative value scale: methods, results and impacts on urology. J Urol 1993, 150:981–987.
13. Holtgrewe HL: American Urological Association survey of transurethral prostatectomy and the impact of changing Medicare reimbursement. Urol Clin North Am 1990, 17:587–593.
14. Monk BJ, Burger RA: Reimbursement for surgical procedures in gynecologic oncology. Curr Opin Oncol 2001, 13:390–393. DOI: 10.1097/00001622-200109000-00013
15. Cherouny P, Nadolski C: Underreimbursement of obstetric and gynecologic invasive services by the resource-based relative value scale. Obstet Gynecol 1996, 87:328–231. DOI: 10.1016/0029-7844(95)00442-4
16. Holtgrewe HL, Mebust WK, Dowd JB, et al.: Transurethral prostatectomy: practice aspects of the dominant operation in American urology. J Urol 1989, 141:248–253.
17. Birkmeyer JD, Sharp SM, Finlayson SR, et al.: Variation profiles of common surgical procedures. Surgery 1998, 124:917–923.
18. Baine WB, Yu W, Summe JP, Weis KA: Epidemiologic trends in the evaluation and treatment of lower urinary tract symptoms in elderly male Medicare patients from 1991 to 1995. J Urol 1998, 160:816–820. DOI: 10.1016/S0022-5347(01)62794-0
19. Agency for Health Care Policy Research: PORT findings: prostate diseases. Rockville, MD: Department of Health and Human Services; 1995. [AHCPR publication no. 95-0086.]
20. Lanes SF, Sulsky S, Walker AM, et al.: A cost density analysis of benign prostatic hyperplasia. Clin Ther 1996, 18:993–1004. DOI: 10.1016/S0149-2918(96)80055-5
21. Plosker GL, Goa KL: Terazosin: a pharmacoeconomic evaluation of its use in benign prostatic hyperplasia. Pharmacoeconomics 1997, 11:184–197. DOI: 10.2165/00019053-199711020-00008
22. Lowe FC, McDaniel RL, Chmiel JJ, Hillman AL: Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia. Urology 1995, 46:477–483. DOI: 10.1016/S0090-4295(99)80258-1
23. Blute M, Ackerman SJ, Rein AL, et al.: Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part II. Results. Urology 2000, 56:981–987. DOI: 10.1016/S0090-4295(00)00829-3
24. Ackerman SJ, Rein AL, Blute M, et al.: Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part I. Methods. Urology 2000, 56:972–980. This article represents a current evaluation of the cost and quality-oflife issues associated with medical therapies, minimally invasive surgeries, and TURP for BPH. The 5-year cost of therapy figures and 1999 Medicare cost estimates provide insight into the financial impact of cost containment efforts as well as treatment-associated quality of life. DOI: 10.1016/S0090-4295(00)00828-1
25. de Pouvourville G: Differences in the approaches of the doctor, manager, politician and social scientist in health care controversies. Hospital case-mix management methods: an illustration of the manager’s approach in health care controversies. Soc Sci Med 1989, 29:341–349. DOI: 10.1016/0277-9536(89)90282-7
26. Lu-Yao GL, Barry MJ, Chang CH, et al.: Transurethral resection of the prostate among Medicare beneficiaries in the United States: time trends and outcomes. Prostate Patient Outcomes Research Team (PORT). Urology 1994, 44:692–698. DOI: 10.1016/S0090-4295(94)80208-4
27. Weiner DM, McDaniel R, Lowe FC: Urologic manpower issues for the 21st century: assessing the impact of changing population demographics. Urology 1997, 49:335–342. DOI: 10.1016/S0090-4295(96)00492-X
28. Wasson JH, Bubolz TA, Lu-Yao GL, et al.: Transurethral resection of the prostate among Medicare beneficiaries: 1984 to 1997. For the Patient Outcomes Research Team for Prostatic Diseases. J Urol 2000, 164:1212–1215. Health care policies have changed the patient demographics for the patient who is offered TURP for the relief of BPH symptoms. The patients are now typically older and urologists perform fewer procedures, which raises concern that the complication rate associated with TURP will increase. DOI: 10.1016/S0022-5347(05)67143-1
29. Riley G, Lubitz J: Outcomes of surgery among the Medicare aged: surgical volume and mortality. Health Care Financ Rev 1985, 7:37–47.
30. Wasson JH, Bubolz TA, Lu-Yao GL, et al.: Transurethral resection of the prostate among medicare beneficiaries: 1984 to 1997. For the Patient Outcomes Research Team for Prostatic Diseases. J Urol 2000, 164:1212–1215. DOI: 10.1016/S0022-5347(05)67143-1
31. Bruskewitz R: Management of symptomatic BPH in the US: who is treated and how? Eur Urol 1999, 36(Suppl 3):7–13. The increased number of therapeutic options for the treatment of LUTS has resulted in increased medical therapy, decreased surgical therapy, and a change in patient profile for those men who elect therapy. Understanding these trends allows urologists to understand the future of BPH therapy and who will assume treatment costs. DOI: 10.1159/000052343